Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroVive Pharmaceutical has received orphan drug status for NeuroSTAT from the European Commission for the treatment of patients with moderate and severe traumatic brain injury.
Subscribe to our email newsletter
The active ingredient in NeuroSTAT, cyclosporin-A, has been used for immunosuppression such as in organ transplantation, NeuroVive said.
NeuroVive Pharma CEO Mikael Bronnegard said that the orphan drug designation gives access to important regulatory assistance which will greatly facilitate the development of neuroprotective therapy for acute treatment of patients with moderate and severe traumatic brain injury.
NeuroVive CSO Eskil Elmér said that NeuroSTAT cyclosporine has been shown to protect energy-producing mitochondria and counteract brain damage in TBI models.